JACOBIO-B receives USD100.00 million upfront from AstraZeneca under pan-KRAS inhibitor licensing deal

Bulletin Express

03/30

Jacobio Pharmaceuticals Group Co., Ltd. (JACOBIO-B) disclosed that its indirect non-wholly owned subsidiary, Beijing Jacobio, has received an upfront payment of USD100.00 million from AstraZeneca AB. The payment forms part of the Licence and Collaboration Agreement signed on 21 December 2025 for the global development of the pan-KRAS inhibitor JAB-23E73.

According to the announcement dated 30 March 2026, the funds will increase the group’s cash reserves and support subsequent development of its oncology pipeline, which spans KRAS, STING, P53 and MYC pathways. Jacobio operates R&D centres in Beijing, Shanghai and Boston, leveraging its Induced Allosteric Drug Discovery Platform and immunostimulatory antibody-drug conjugate platform.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1114925187"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1114925187\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1114925187?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-30 08:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1114925187","market":"us","top_or_hot":-1,"title":"JACOBIO-B receives USD100.00 million upfront from AstraZeneca under pan-KRAS inhibitor licensing deal","media":"Bulletin Express","content":"<p>Jacobio Pharmaceuticals Group Co., Ltd. (JACOBIO-B) disclosed that its indirect non-wholly owned subsidiary, Beijing Jacobio, has received an upfront payment of USD100.00 million from AstraZeneca AB. The payment forms part of the Licence and Collaboration Agreement signed on 21 December 2025 for the global development of the pan-KRAS inhibitor JAB-23E73.</p>\n<p>According to the announcement dated 30 March 2026, the funds will increase the group’s cash reserves and support subsequent development of its oncology pipeline, which spans KRAS, STING, P53 and MYC pathways. Jacobio operates R&D centres in Beijing, Shanghai and Boston, leveraging its Induced Allosteric Drug Discovery Platform and immunostimulatory antibody-drug conjugate platform.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JACOBIO-B receives USD100.00 million upfront from AstraZeneca under pan-KRAS inhibitor licensing deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJACOBIO-B receives USD100.00 million upfront from AstraZeneca under pan-KRAS inhibitor licensing deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-30 08:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Jacobio Pharmaceuticals Group Co., Ltd. (JACOBIO-B) disclosed that its indirect non-wholly owned subsidiary, Beijing Jacobio, has received an upfront payment of USD100.00 million from AstraZeneca AB. The payment forms part of the Licence and Collaboration Agreement signed on 21 December 2025 for the global development of the pan-KRAS inhibitor JAB-23E73.</p>\n<p>According to the announcement dated 30 March 2026, the funds will increase the group’s cash reserves and support subsequent development of its oncology pipeline, which spans KRAS, STING, P53 and MYC pathways. Jacobio operates R&D centres in Beijing, Shanghai and Boston, leveraging its Induced Allosteric Drug Discovery Platform and immunostimulatory antibody-drug conjugate platform.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01167","symbol_name":"加科思-B","start_time":0,"source_url":"","article_id":"1114925187","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1114925187","pubTimestamp":1774829001,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Jacobio Pharmaceuticals Group Co., Ltd. (JACOBIO-B) disclosed that its indirect non-wholly owned subsidiary, Beijing Jacobio, has received an upfront payment of USD100.00 million from AstraZeneca AB....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01167":"加科思-B"},"translate_title":"JACOBIO-B根据泛KRAS抑制剂许可协议从阿斯利康预付款1亿美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01167":1},"content_text":"Jacobio Pharmaceuticals Group Co., Ltd. (JACOBIO-B) disclosed that its indirect non-wholly owned subsidiary, Beijing Jacobio, has received an upfront payment of USD100.00 million from AstraZeneca AB. The payment forms part of the Licence and Collaboration Agreement signed on 21 December 2025 for the global development of the pan-KRAS inhibitor JAB-23E73.\nAccording to the announcement dated 30 March 2026, the funds will increase the group’s cash reserves and support subsequent development of its oncology pipeline, which spans KRAS, STING, P53 and MYC pathways. Jacobio operates R&D centres in Beijing, Shanghai and Boston, leveraging its Induced Allosteric Drug Discovery Platform and immunostimulatory antibody-drug conjugate platform.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}